World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5784)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

171

HTML

2351

Figures (1-4)

502

Sum=3024

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

316

Download

1171

Sum=1487

Publishing Process of This Article

Item

Count

Browse

187

Download

867

Sum=1054

Mar 26, 2024 (publication date) through Apr 18, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Xu X, Jiang JW, Lu BY, Li XX. Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report. World J Clin Cases 2024; 12(9): 1685-1690 [PMID: 38576732 DOI: 10.12998/wjcc.v12.i9.1685]
URL:	https://www.wjgnet.com/2307-8960/full/v12/i9/1685.htm

Number	Citing Articles
1	Jonathan Soldera. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. World Journal of Clinical Cases 2024; 12(24): 5468-5472 doi: 10.12998/wjcc.v12.i24.5468 Abstract(695) \| Core Tip(703) \| Full Article(HTML)(2095) \| Full Article with Cover (PDF)-7275K(288) \| Audio-140K(20) \| Peer-Review Report-172K(139) \| Answering Reviewers-76K(109) \| Full Article (PDF)-6886K(234) \| Full Article (XML)-50K(128) \| Times Cited (9) \| Total Visits (6436) \| Open
2	Wilfredo Jhoel Javier-Rojas, Alvin Boyd Newman-Caro, Mamoon Ghellai, Vamsee Mupparaju, Sreekanth Chandrupatla, Siddharth Mathur, Yizhi Lin. First Reported Case of Upadacitinib-Associated Cytomegalovirus Viremia and Suspected Pneumonitis in Ulcerative Colitis. ACG Case Reports Journal 2026; 13(4) doi: 10.14309/crj.0000000000002049
3	Infliximab/Vedolizumab. Reactions Weekly 2025; 2049(1): 186 doi: 10.1007/s40278-025-78801-z
4	Antonio M Caballero-Mateos, Guillermo Arturo Cañadas-de la Fuente. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management. World Journal of Gastroenterology 2024; 30(35): 3942-3953 doi: 10.3748/wjg.v30.i35.3942 Abstract(626) \| Core Tip(708) \| Full Article(HTML)(3851) \| Full Article with Cover (PDF)-2954K(181) \| Audio-1388K(25) \| Peer-Review Report-220K(125) \| Answering Reviewers-74K(110) \| Full Article (PDF)-2682K(303) \| Full Article (XML)-189K(129) \| Times Cited (11) \| Total Visits (8589) \| Open
5	Jessy G Fadel, Said G Farhat. Refractory ulcerative colitis: Upadacitinib versus other biologics. World Journal of Clinical Cases 2024; 12(31): 6425-6427 doi: 10.12998/wjcc.v12.i31.6425 Abstract(669) \| Core Tip(691) \| Full Article(HTML)(1807) \| Full Article with Cover (PDF)-1540K(105) \| Audio-777K(15) \| Peer-Review Report-214K(111) \| Answering Reviewers-29K(113) \| Full Article (PDF)-326K(193) \| Full Article (XML)-21K(116) \| Times Cited (0) \| Total Visits (6072) \| Open
6	Javier P Gisbert, María Chaparro. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review. Journal of Crohn's and Colitis 2025; 19(2) doi: 10.1093/ecco-jcc/jjaf021